S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
NASDAQ:IPSC

Century Therapeutics Stock Competitors

$15.23
-0.43 (-2.75%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.00
$15.87
50-Day Range
$15.66
$29.25
52-Week Range
$14.47
$32.90
Volume
142,005 shs
Average Volume
177,087 shs
Market Capitalization
$832.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Century Therapeutics (NASDAQ:IPSC) Vs. SWTX, SANA, RLAY, RXRX, VALN, KYMR, IOVA, TIL, ALLO, and IBRX

Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include SpringWorks Therapeutics (SWTX), Sana Biotechnology (SANA), Relay Therapeutics (RLAY), Recursion Pharmaceuticals (RXRX), Valneva (VALN), Kymera Therapeutics (KYMR), Iovance Biotherapeutics (IOVA), Instil Bio (TIL), Allogene Therapeutics (ALLO), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry.

Century Therapeutics vs.

Century Therapeutics (NASDAQ:IPSC) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, community ranking, dividends, valuation and analyst recommendations.

Century Therapeutics received 2 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 66.67% of users gave Century Therapeutics an outperform vote while only 44.44% of users gave Sana Biotechnology an outperform vote.

CompanyUnderperformOutperform
Century TherapeuticsOutperform Votes
6
66.67%
Underperform Votes
3
33.33%
Sana BiotechnologyOutperform Votes
4
44.44%
Underperform Votes
5
55.56%

Century Therapeutics currently has a consensus price target of $36.00, indicating a potential upside of 136.38%. Sana Biotechnology has a consensus price target of $38.50, indicating a potential upside of 130.95%. Given Century Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Century Therapeutics is more favorable than Sana Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Century Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Sana Biotechnology
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

35.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 50.6% of Sana Biotechnology shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Century TherapeuticsN/AN/AN/AN/AN/A
Sana BiotechnologyN/AN/A-$285.30 million-$9.29-1.79

Century Therapeutics' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
Century Therapeutics N/A N/A N/A
Sana Biotechnology N/A -40.60% -19.70%

In the previous week, Century Therapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 2 mentions for Century Therapeutics and 0 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.83 beat Century Therapeutics' score of -0.01 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
Century Therapeutics Neutral
Sana Biotechnology Positive

Summary

Century Therapeutics beats Sana Biotechnology on 8 of the 10 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Century Therapeutics (NASDAQ:IPSC) vs. Its Competitors

TypeCentury TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$832.18M$3.71B$4.77B$7.64B
Dividend YieldN/A2.15%2.09%2.51%
P/E RatioN/A9.3722.2422.08
Price / SalesN/A2,643.522,448.48252.47
Price / CashN/A105.5540.47137.79
Price / BookN/A5.769.1410.02
Net IncomeN/A$2.48M$95.90M$154.15M
7 Day Performance-11.45%-7.56%-5.88%-5.40%
1 Month Performance-34.38%-19.49%-15.10%-11.90%
1 Year PerformanceN/A-7.56%9.42%23.55%

Century Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SWTX
SpringWorks Therapeutics
2.5198 of 5 stars
$66.21
-7.0%
$117.50
-77.5%
+5.9%$3.26B$35M-30.2378
SANA
Sana Biotechnology
1.5699 of 5 stars
$16.67
-10.2%
$38.50
-131.0%
N/A$3.15BN/A-1.79265
RLAY
Relay Therapeutics
2.2848 of 5 stars
$28.18
-4.5%
$51.25
-81.9%
-42.8%$3.04B$82.65M0.002,020
RXRX
Recursion Pharmaceuticals
1.8381 of 5 stars
$17.72
-7.3%
$33.33
-88.1%
N/A$2.99B$3.96M0.00218High Trading Volume
VALN
Valneva
1.2682 of 5 stars
$54.05
-16.3%
$36.00
-33.4%
N/A$2.84B$126.02M0.00500Gap Down
High Trading Volume
KYMR
Kymera Therapeutics
2.1199 of 5 stars
$53.15
-1.9%
$76.43
-43.8%
+4.3%$2.73B$34.03M-31.4575
IOVA
Iovance Biotherapeutics
1.6833 of 5 stars
$16.55
-6.4%
$38.20
-130.8%
-57.4%$2.60BN/A-8.03241
TIL
Instil Bio
2.1164 of 5 stars
$19.94
-9.7%
$30.40
-52.5%
N/A$2.57B$140K0.00150High Trading Volume
ALLO
Allogene Therapeutics
2.5944 of 5 stars
$17.62
-8.3%
$36.23
-105.6%
-39.4%$2.51BN/A-9.37265Short Interest ↑
IBRX
ImmunityBio
1.8716 of 5 stars
$5.84
-6.5%
$25.00
-328.1%
N/A$2.32B$110K0.00171Upcoming Earnings
BCRX
BioCryst Pharmaceuticals
2.2014 of 5 stars
$11.44
-3.8%
$20.20
-76.6%
+135.5%$2.05B$17.81M-9.01246
RVMD
Revolution Medicines
2.3998 of 5 stars
$26.10
-5.9%
$35.83
-37.3%
-33.8%$1.92B$42.98M-11.01125
EDIT
Editas Medicine
2.1351 of 5 stars
$27.72
-8.3%
$57.27
-106.6%
-4.8%$1.90B$90.73M-8.56235
DNA
Ginkgo Bioworks
1.825 of 5 stars
$8.65
-18.2%
$14.50
-67.6%
N/A$1.87BN/A0.002,021Analyst Revision
High Trading Volume
NSTG
NanoString Technologies
1.8731 of 5 stars
$37.35
-3.8%
$67.50
-80.7%
-31.4%$1.71B$117.32M-15.31579
VCEL
Vericel
1.8548 of 5 stars
$35.66
-0.3%
$53.00
-48.6%
+43.8%$1.67B$124.18M-3,566.00273Insider Selling
Gap Down
CCCC
C4 Therapeutics
2.3579 of 5 stars
$34.01
-4.0%
$48.50
-42.6%
+18.8%$1.65B$33.19M0.0099Analyst Downgrade
ALEC
Alector
2.3714 of 5 stars
$19.45
-6.2%
$40.33
-107.4%
+48.9%$1.58B$21.10M-37.40171High Trading Volume
SRNE
Sorrento Therapeutics
1.9917 of 5 stars
$4.95
-11.3%
$28.67
-479.1%
-29.1%$1.52B$39.99M-4.02502
KRYS
Krystal Biotech
2.2464 of 5 stars
$68.11
-3.9%
$115.33
-69.3%
+32.0%$1.51BN/A-25.1375Analyst Report
High Trading Volume
ATRA
Atara Biotherapeutics
1.8121 of 5 stars
$17.09
-5.4%
$30.33
-77.5%
-24.0%$1.51BN/A-4.72437
INBX
Inhibrx
2.1064 of 5 stars
$36.90
-8.0%
$53.00
-43.6%
+20.8%$1.40B$12.89M-17.8388Analyst Downgrade
Short Interest ↓
News Coverage
CHRS
Coherus BioSciences
2.0648 of 5 stars
$17.75
-1.7%
$25.75
-45.1%
-4.2%$1.36B$475.82M-5.65317
RGNX
REGENXBIO
2.4873 of 5 stars
$30.59
-3.4%
$58.25
-90.4%
-16.0%$1.31B$154.57M-5.92306
REPL
Replimune Group
2.3865 of 5 stars
$27.66
-4.8%
$55.00
-98.8%
-40.8%$1.30BN/A-14.26152
IMCR
Immunocore
1.5082 of 5 stars
$28.71
-11.9%
$54.75
-90.7%
N/A$1.24B$38.67M0.002,020News Coverage
ITOS
iTeos Therapeutics
2.1598 of 5 stars
$34.82
-0.7%
$46.25
-32.8%
+30.3%$1.23BN/A120.0762Analyst Downgrade
Insider Selling
Short Interest ↓
SGMO
Sangamo Therapeutics
1.8881 of 5 stars
$8.10
-4.3%
$23.00
-184.0%
-15.3%$1.18B$118.19M-6.38413Insider Selling
OCGN
Ocugen
1.8914 of 5 stars
$5.76
-9.5%
$7.90
-37.2%
+1,881.2%$1.15B$42.62M0.0015
ALVR
AlloVir
2.2998 of 5 stars
$17.49
-3.6%
$46.67
-166.8%
-55.2%$1.14B$170K0.0053
RUBY
Rubius Therapeutics
2.0998 of 5 stars
$12.07
-4.5%
$26.33
-118.2%
+92.8%$1.08BN/A-5.69204
HUMA
Humacyte
2.4917 of 5 stars
$10.39
-5.3%
$17.25
-66.0%
N/A$1.07BN/A0.00N/A
CRBU
Caribou Biosciences
1.9848 of 5 stars
$17.07
-5.5%
$30.60
-79.3%
N/A$1.03BN/A0.002,021Analyst Report
Short Interest ↑
Analyst Revision
News Coverage
PCVX
Vaxcyte
1.6065 of 5 stars
$19.32
-5.6%
N/A-34.8%$1.02BN/A-10.7958
SRRK
Scholar Rock
2.3865 of 5 stars
$25.10
-2.6%
$65.00
-159.0%
-48.4%$881.21M$15.40M-7.36119
IMVT
Immunovant
1.9667 of 5 stars
$7.60
-4.3%
$16.00
-110.5%
-84.0%$874MN/A-5.9868Positive News
BCAB
BioAtla
2.5333 of 5 stars
$22.50
-2.2%
$65.20
-189.8%
N/A$828.81M$430K0.0036Insider Selling
High Trading Volume
ICVX
Icosavax
1.825 of 5 stars
$21.07
-2.8%
$48.57
-130.5%
N/A$822.62MN/A0.002,021
SOPH
SOPHiA Genetics
1.7 of 5 stars
$12.91
-1.2%
$23.00
-78.2%
N/A$817.69M$28.40M0.00N/A
VXRT
Vaxart
1.8464 of 5 stars
$6.32
-5.9%
$13.75
-117.6%
-8.1%$793.14M$4.05M-11.7028
GRTS
Gritstone bio
2.3998 of 5 stars
$11.58
-5.4%
$22.33
-92.9%
+312.5%$787.30M$4.04M-9.05169Options Volume
TNYA
Tenaya Therapeutics
1.7048 of 5 stars
$18.89
-5.1%
$36.00
-90.6%
N/A$779.80MN/A0.002,021
MGTX
MeiraGTx
2.4514 of 5 stars
$17.54
-5.6%
$26.50
-51.1%
+31.3%$779.64M$15.56M-9.53219Short Interest ↑
GLUE
Monte Rosa Therapeutics
1.3915 of 5 stars
$16.28
-5.2%
$32.00
-96.6%
N/A$757.12MN/A0.0060
OMGA
Omega Therapeutics
1.6681 of 5 stars
$15.70
-12.9%
$29.50
-87.9%
N/A$750.07MN/A0.002,021
AGEN
Agenus
2.1598 of 5 stars
$2.92
-3.4%
$11.00
-276.7%
-16.8%$749.95M$88.17M-24.33359Analyst Upgrade
FNCH
Finch Therapeutics Group
1.5798 of 5 stars
$15.32
-5.3%
$29.33
-91.5%
N/A$727.38MN/A0.00131High Trading Volume
STRO
Sutro Biopharma
2.0531 of 5 stars
$15.56
-4.4%
$30.83
-98.2%
-0.7%$719.96M$42.72M-5.29192
CGEM
Cullinan Oncology
2.5333 of 5 stars
$16.21
-6.0%
$51.75
-219.2%
N/A$708.13MN/A0.0024
BLUE
bluebird bio
2.3698 of 5 stars
$9.95
-6.8%
$18.07
-81.6%
-77.0%$697.57M$250.73M-0.781,213
This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.